Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically detailing changes in their interests in the company's Ordinary shares and American Depository Shares (ADSs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is strictly a regulatory disclosure regarding director share awards and contains no financial performance data.
Material Changes
On December 31, 2010, Non-Executive Directors received provisional allocations of awards over Ordinary shares and ADSs through the annual reinvestment of dividends paid throughout 2010. These allocations were informed to the Company and Directors on January 4, 2011.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of specific share award transactions in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Important Facts for Investors
- Transaction Type: Annual dividend reinvestment awards for Non-Executive Directors.
- Valuation Metrics: Ordinary shares were allocated at an average price of £12.55; ADSs were allocated at an average price of $39.18.
- Participants: Awards were distributed to Sir Christopher Gent, Prof Sir Roy Anderson, Dr Stephanie Burns, Mr Lawrence Culp, Sir Crispin Davis, Sir Deryck Maughan, Mr James Murdoch, Dr Daniel Podolsky, Mr Tom de Swaan, and Sir Robert Wilson.
- Reporting Date: The notification was signed and dated January 5, 2011, by Victoria Whyte, Company Secretary.